WO1996038728A1 - A METHOD FOR MEASURING THE A2a RECEPTOR BINDING ACTIVITY OF COMPOUNDS OF PHARMACOLOGICAL INTEREST BY THE USE OF THE TRITIATED LIGAND (3H)-SCH 58261 - Google Patents
A METHOD FOR MEASURING THE A2a RECEPTOR BINDING ACTIVITY OF COMPOUNDS OF PHARMACOLOGICAL INTEREST BY THE USE OF THE TRITIATED LIGAND (3H)-SCH 58261 Download PDFInfo
- Publication number
- WO1996038728A1 WO1996038728A1 PCT/EP1996/002348 EP9602348W WO9638728A1 WO 1996038728 A1 WO1996038728 A1 WO 1996038728A1 EP 9602348 W EP9602348 W EP 9602348W WO 9638728 A1 WO9638728 A1 WO 9638728A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- receptors
- brain tissue
- receptor
- mammalian brain
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- G01N33/5735—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes co-enzymes or co-factors, e.g. NAD, ATP
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- Adenosine modulates a wide range of physiological functions by interaction with different receptor subtypes named Al, A2a, A2b and A3 [Pharmacol. Rev., 46, 143, (1994)]. While the availability of Al receptor ligands led to rapid progress in the characterization of this receptor subtype, the pharmacology of A2a adenosine receptors was hampered by the lack of selective ligands [Med. Res. Rev., 12, 423, (1992)]. In the past, using different strategies to block the interaction with Al receptors [Naunyn-Schmiedeberg's Arch. Pharmacol., 325, 218, (1984); Mol.
- the A2a selective antagonist ( 3 H)-(E,18%-Z,82%)-8-(3,4-dimethoxystyryl)-l,3-dipro- pylxanthine [( 3 H)-KF 17837S] has been indicated to interact directly with the A2a adenosine receptor in rat striatal tissue, showing a specific binding of 60-70% [Mol. Pharmacol., 46, 817, (1995)].
- One aspect of the present invention is the preparation of the labeled compound 5-amino-7-[2- (2 1 ,4' ,5' 3 H) ⁇ henetyl]-2-(2-furyl)-pyrazolo-[4,3-e]- -1,2,4-triazolo[l,5-c]pyrimidine (hereinafter referred to as ( 3 H)-Compound) .
- the preferred label of the invention has the purpose of facilitating the measurement of the relative binding affinity values, preferably by introducing tritium ( H) atoms, and more preferably, located on the phenethyl group at the positions 2', 4' and 5'.
- the second aspect of the invention is a method for determining the adenosine A2a receptor binding affinity of a test compound; said method consisting in:
- test compound may be synthesized and/or purified from natural source such as animal or plant tissue.
- kit for determining the A2a binding activity of a test compound comprising:
- the tissue was homogenised in a Polytron PTA 10 Probe (setting 5, 20 sec) in 25 volumes (v/v) of 50 mM Tris-HCl buffer, pH 7,4, centrifuged at 48,000 x g for 10 min at 4°C and resuspended in Tris-HCl containing 2 units/ml of adenosine deaminase. After 30 min of incubation at 37°C, the membranes were centrifuged and pellet was stored at -70°C.
- Binding Assay Saturation binding experiments were carried out in polypropylene test tubes containing an aliquot of striatal membranes (100 ug of protein /assay) in incubation buffer (50 mM Tris-HCl, pH 7.4) and 11 different concentrations of ( 3 H)-Compound (0.0625-64 nM) , in a final volume of 0.5 ml Non specific binding was defined in the presence of NECA 50 uM. All assays were performed at 25°C for 30 min, the separation of the free radioligand from the one bound to the receptor was carried out by fast filtration through Whatman GF/B filters using the Brandel cell harvester (Gaithersburg, MD, USA) .
- Binding parameters were estimated by using the computerized program LIGAND [Anal. Biochem. , 107, 220, (1980)]. Results
- ( 3 H)-Compound labeling directly the adenosine A2a striatal receptor, proves to be an excellent means for studying this adenosine A2a receptor subtype in mammalian brain.
- Clear advantages over other A2a antagonist radioligand proposed for this purpose are the high receptor affinity and the low non specific binding.
- a kit containing the necessary components to perform the assays as described above, as well as a method to utilize such kit, can be considered essential for evaluating the interaction of a test compound with A2a adenosine receptors in mammalian brain tissues.
- the ( 3 H)-Compound has the characteristics to become a useful tool for the investigation of A2a receptors distributed in peripheral tissues, such as vascular preparations, platelets and neutrophils, in which their presence has been clearly demonstrated [TiPS, 14, 360, (1993)].
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU61238/96A AU6123896A (en) | 1995-06-02 | 1996-06-01 | A method for measuring the a2a receptor binding activity of compounds of pharmacological interest by the use of the trit iated ligand (3h)-sch 58261 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI951155A IT1275420B (en) | 1995-06-02 | 1995-06-02 | METHOD FOR MEASURING THE BINDING AFFINITY TO THE A2A RECEPTOR OF ADENOSINE OF COMPONENTS OF PHARMACOLOGICAL INTEREST THROUGH THE USE OF THE TRITIUM LIGAND (3H) -SCH 58261 |
ITMI95A001155 | 1995-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996038728A1 true WO1996038728A1 (en) | 1996-12-05 |
Family
ID=11371733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/002348 WO1996038728A1 (en) | 1995-06-02 | 1996-06-01 | A METHOD FOR MEASURING THE A2a RECEPTOR BINDING ACTIVITY OF COMPOUNDS OF PHARMACOLOGICAL INTEREST BY THE USE OF THE TRITIATED LIGAND (3H)-SCH 58261 |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6123896A (en) |
IT (1) | IT1275420B (en) |
WO (1) | WO1996038728A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6407236B1 (en) | 1998-09-16 | 2002-06-18 | Medco Research, Inc. | Adenosine A3 receptor modulators |
WO2004079329A2 (en) * | 2003-03-07 | 2004-09-16 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
US6921825B2 (en) | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
WO2007038284A1 (en) | 2005-09-23 | 2007-04-05 | Schering Corporation | 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE |
US7759321B2 (en) | 2003-03-07 | 2010-07-20 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
US7790698B2 (en) | 2003-03-07 | 2010-09-07 | Cambridge Biotechnology Ltd | Use of adenosine receptor agonists in therapy |
US8252766B2 (en) | 2002-12-09 | 2012-08-28 | Cbt Development Limited | Use of spongosine for the treatment of pain |
WO2018089901A3 (en) * | 2016-11-14 | 2019-06-06 | Joslin Diabetes Center | Exosome delivery system |
-
1995
- 1995-06-02 IT ITMI951155A patent/IT1275420B/en active IP Right Grant
-
1996
- 1996-06-01 WO PCT/EP1996/002348 patent/WO1996038728A1/en active Application Filing
- 1996-06-01 AU AU61238/96A patent/AU6123896A/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
A. NEGRETTI ET AL.: "In vitro pharmacological profile of the new non-xanthine A2a adenosine antagonist 8FB-PTP", RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, vol. 87, no. 1, 1 January 1995 (1995-01-01), WSETBURY NY USA, pages 87 - 88, XP000603784 * |
C. ZOCCHI ET AL.: "Binding of the radioligand (3H)-SCH 58261, a new non-xanthine A2a adenosine receptor antagonist, to rat striatal membranes", BRITISH JOURNAL OF PHARMACOLOGY, vol. 117, no. 7, 1 April 1996 (1996-04-01), LONDON UK, pages 1381 - 1386, XP000603818 * |
P.G. BARALDI ET AL.: "Synthesis of new pyrazolo(4,3-e)1,2,4-triazolo(1,5-c) pyrimidine and 1,2,3-triazolo(4,5-c)pyrimidine displaying potent and selective activity as A2a adenosine receptor antagonists.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 4, no. 21, 1 January 1994 (1994-01-01), LONDON UK, pages 2539 - 2544, XP000603773 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921825B2 (en) | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
US6407236B1 (en) | 1998-09-16 | 2002-06-18 | Medco Research, Inc. | Adenosine A3 receptor modulators |
US8252766B2 (en) | 2002-12-09 | 2012-08-28 | Cbt Development Limited | Use of spongosine for the treatment of pain |
JP4701330B2 (en) * | 2003-03-07 | 2011-06-15 | シービーティ・デベロップメント・リミテッド | Identification of therapeutic compounds |
JP2006519602A (en) * | 2003-03-07 | 2006-08-31 | ケンブリッジ・バイオテクノロジー・リミテッド | Identification of therapeutic compounds |
US7759321B2 (en) | 2003-03-07 | 2010-07-20 | Cambridge Biotechnology Ltd | Compounds for the treatment of pain |
US7790698B2 (en) | 2003-03-07 | 2010-09-07 | Cambridge Biotechnology Ltd | Use of adenosine receptor agonists in therapy |
WO2004079329A3 (en) * | 2003-03-07 | 2004-12-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
WO2004079329A2 (en) * | 2003-03-07 | 2004-09-16 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
WO2007038284A1 (en) | 2005-09-23 | 2007-04-05 | Schering Corporation | 7-[2-[4-(6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL)-1-PIPERAZINYL]ETHYL]-2-(1-PROPYNYL)-7H-PYRAZOLO-[4,3-e]-[1,2,4]-TRIAZOLO-[1,5-c]-PYRIMIDIN-5 AMINE |
WO2018089901A3 (en) * | 2016-11-14 | 2019-06-06 | Joslin Diabetes Center | Exosome delivery system |
US11519008B2 (en) | 2016-11-14 | 2022-12-06 | Joslin Diabetes Center | Exosome delivery system |
Also Published As
Publication number | Publication date |
---|---|
ITMI951155A1 (en) | 1996-12-02 |
AU6123896A (en) | 1996-12-18 |
ITMI951155A0 (en) | 1995-06-02 |
IT1275420B (en) | 1997-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Varani et al. | Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]‐CGS 21680 binding | |
Ongini et al. | Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors | |
Bruns et al. | Binding of the A 1-selective adenosine antagonist 8-cyclopentyl-1, 3-dipropylxanthine to rat brain membranes | |
Jacobson et al. | [3H] xanthine amine congener of 1, 3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. | |
Hüttemann et al. | R a Adenosine receptors in human platelets: characterization by 5′-N-ethylcarboxamido [3 H] adenosine binding in relation to adenylate cyclase activity | |
Varani et al. | [3H] MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors | |
Lohse et al. | 8-Cyclopentyl-1, 3-dipropylxanthine (DPCPX)—a selective high affinity antagonist radioligand for A 1 adenosine receptors | |
Zocchi et al. | Binding of the radioligand [3H]‐SCH 58261, a new non‐xanthine A2A adenosine receptor antagonist, to rat striatal membranes | |
Murphree et al. | Human A2A adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gβ4 | |
Ji et al. | Use of the triazolotriazine [3H] ZM 241385 as a radioligand at recombinant human A2B adenosine receptors | |
Klotz et al. | Photoaffinity labeling of A1-adenosine receptors. | |
Gessi et al. | Pharmacological and biochemical characterization of A3 adenosine receptors in Jurkat T cells | |
Patel et al. | Characterization of adenosine receptors in brain using N6 cyclohexyl [3H] adenosine | |
Palmer et al. | 125I-4-(2-[7-amino-2-{2-furyl}{1, 2, 4} triazolo {2, 3-a}{1, 3, 5} triazin-5-yl-amino] ethyl) phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor | |
Williams et al. | Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue | |
Fredholm et al. | [3H] SCH 58261, a selective adenosine A2A receptor antagonist, is a useful ligand in autoradiographic studies | |
Cunha et al. | G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors | |
Stewart et al. | [3H] OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors | |
WO1996038728A1 (en) | A METHOD FOR MEASURING THE A2a RECEPTOR BINDING ACTIVITY OF COMPOUNDS OF PHARMACOLOGICAL INTEREST BY THE USE OF THE TRITIATED LIGAND (3H)-SCH 58261 | |
Williams et al. | Characterization of Adenosine Receptors in the PC 12 Pheochromocytoma Cell Line Using Radioligand Binding: Evidence for A‐2 Selectivity | |
Hawkins et al. | Effects of chronic administration of caffeine on adenosine A1 and A2 receptors in rat brain | |
Gao et al. | Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A1 and A3 adenosine receptors | |
Varani et al. | Characterization of A2A adenosine receptors in human lymphocyte membranes by [3H]‐SCH 58261 binding | |
Alexander et al. | [3H] ZM241385—an antagonist radioligand for adenosine A2A receptors in rat brain | |
Schwabe et al. | [125 I] N 6-p-Hydroxyphenylisopropyladenosine, a new ligand for R i adenosine receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1998 973069 Date of ref document: 19980330 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |